PT-141

PT-141 10 MG

Manufacturer: Hilma Biocare

Package: 10 mg/vial

Common Names: PT-141, Bremelanotide, Bremelanotide Peptide

Info: PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide derived from the melanocortin system. It is primarily researched for its interaction with melanocortin receptors, particularly MC3R and MC4R, which are involved in central nervous system signaling and sexual-response pathways.

Unlike PDE-5 inhibitors, PT-141 does not primarily act through vascular phosphodiesterase inhibition. Its activity is associated with central melanocortin receptor signaling.

Effects

Melanocortin Receptor Research: PT-141 has been investigated for activity at MC3R and MC4R.

Sexual Function Research: Bremelanotide has been studied for its potential effects on sexual desire, arousal, and related neurobehavioral mechanisms.

Central Signaling: Its primary mechanism involves melanocortin pathways within the central nervous system.

Dosage Range and Duration of Use

PT-141 10 mg (10 mg/vial): Each vial contains 10 mg of lyophilized PT-141 and requires reconstitution before parenteral administration.

Clinical pharmaceutical protocols use 1.75 mg subcutaneously, generally at least 45 minutes before anticipated sexual activity, with no more than one dose within 24 hours and eight doses per month. These parameters apply to approved pharmaceutical formulations and should not automatically be applied to research preparations.

Side Effects

Possible adverse effects include nausea, flushing, headache, dizziness, fatigue, temporary increases in blood pressure, and injection-site reactions. Hypersensitivity reactions are also possible.

Post-Cycle Therapy

PT-141 is not an anabolic steroid or androgen and is not generally considered a conventional post-cycle therapy compound.

Storage:

Store lyophilized PT-141 in a cool, dry place protected from light and excessive heat. After reconstitution, storage and stability depend on the diluent, preparation method, and manufacturer specifications.